The FDA today declared the national deficit of GLP-1 diet drugs at an end. Well, at least for Novo Nordisk's Ozempic and Wegovy. Novo Nordisk sales should be going up, and Hims & Hers Health's ...

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other best drug stocks to buy now.

Jerry Jones and the Dallas Cowboys are in a tough position entering the NFL offseason. After missing the playoffs in 2024, the team has moved on from Mike McCarthy, but they don't have a lot of ...

In September, Volkswagen will unveil the electric T-Cross at IAA Mobility, dubbed the ID.2X. CEO Thomas Schäfer confirmed the mini electric SUV’s name on Thursday, which is expected to go in ...

Now, semaglutide maker Novo Nordisk is chiming in. The commercial takes aim at the broader U.S. weight loss industry as well as makers of GLP-1 drugs for obesity, which are “priced for profits ...

Novo Nordisk A/S dominates in diabetes and weight-loss drugs, particularly with semaglutide, making it a strong buy. Record investments in 2024 to enhance supply chain and production capacity ...

Europe's largest pharmaceutical firm, Novo Nordisk, reported fourth-quarter earnings that surpassed analysts' expectations. The company’s shares jumped more than 6% at the market open in Europe ...

By Eshe Nelson Reporting from London Novo Nordisk, the Danish pharmaceutical company behind Ozempic and Wegovy, capped off a somewhat turbulent 2024, reporting profit and revenue on Wednesday that ...

LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed ...